<DOC>
	<DOCNO>NCT00049101</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Erlotinib may stop growth tumor cell block enzymes necessary tumor cell growth . Combining erlotinib combination chemotherapy may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combine erlotinib oxaliplatin , leucovorin , fluorouracil treat patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Erlotinib Combination Chemotherapy Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose erlotinib administer oxaliplatin , leucovorin calcium , fluorouracil patient metastatic colorectal cancer . - Determine pharmacokinetics regimen patient . - Determine antitumor activity regimen patient . - Determine time progression patient treat regimen . - Determine objective response rate response duration patient treat regimen . - Determine safety tolerability regimen patient . OUTLINE : This dose-escalation study erlotinib . - Phase I : During first week first course , patient receive oral erlotinib daily alone . Patients begin regular schedule comprise oral erlotinib daily , oxaliplatin IV 2 hour day 1 , leucovorin calcium IV 2 hour fluorouracil IV 22 hour day 1 2 . Treatment repeat every 2 week least 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos erlotinib maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive erlotinib MTD plus oxaliplatin , leucovorin calcium , fluorouracil phase I. Erlotinib may administer alone toxicity cause oxaliplatin , leucovorin calcium , fluorouracil . Patients follow least 6 month disease progression . PROJECTED ACCRUAL : A total 4-18 patient accrued phase I study within 1-4 month . A total 50 patient accrue phase II study within 10 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm colon rectal cancer Metastatic unresectable disease Unidimensionally measurable disease require phase II At least 20 mm xray , CT scan , MRI , photography The following consider measurable : Pleural effusion ascites Osteoblastic lesion Evidence disease bone scan alone Progressive irradiated lesion alone Bone marrow involvement Brain metastases Malignant hepatomegaly physical exam alone Chemical marker ( e.g. , carcinoembryonic antigen ) Recurrent disease surgery radiotherapy consider measurable long follow criterion meet : At least 4 week since prior surgery radiotherapy Measurable disease exist outside radiation port clear progression exists within radiation port Tissue accessible immunohistochemical evidence epidermal growth factor receptor expression metastatic site ( phase II ) No know brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy More 3 month Hematopoietic WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin normal AST/ALT great 2.5 time upper limit normal Renal Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular No unstable angina pectoris No symptomatic congestive heart failure No cardiac arrhythmia No uncontrolled hypertension ( systolic blood pressure great 150 mm Hg ) Opthalmic No abnormality cornea ( e.g. , severe dry eye syndrome Sjogren 's syndrome ) No congenital abnormality ( e.g. , Fuch 's dystrophy ) No abnormal slitlamp examination use vital dye ( e.g. , fluorescein BengalRose ) No abnormal corneal sensitivity test ( e.g. , Schirmer test similar tearproduction test ) Mild dry eye syndrome allow patient use artificial tear ophthalmologist concurs Gastrointestinal No gastrointestinal tract disease result inability take oral medication requirement IV alimentation No active peptic ulcer disease Other Must able willing undergo mediport insertion Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year except previously excise inactive basal cell squamous cell skin cancer No prior allergic reaction attribute compound similar chemical biological composition erlotinib study drug ( e.g. , epidermal growth factor inhibitor like cetuximab ) No significant traumatic injury within past 3 week No peripheral neuropathy grade 2 great No ongoing active infection No uncontrolled concurrent illness would preclude study entry No psychiatric illness social situation would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Phase I : Prior chemotherapy allow Phase II : No prior chemotherapy metastatic disease Prior adjuvant therapy allow disease progress adjuvant therapy No prior oxaliplatin Endocrine therapy Not specify Radiotherapy See Disease Characteristics More 4 week since prior radiotherapy recover Surgery See Disease Characteristics More 3 week since prior major surgery recover No prior surgical procedure affect absorption Other No concurrent investigational agent No concurrent anticancer agent therapy ( commercial investigational ) No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>